Humacyte Stock Options
| HUMA Stock | USD 1.27 0.02 1.55% |
Humacyte's latest option contracts expiring on March 20th 2026 are carrying combined implied volatility of 1.69 with a put-to-call open interest ratio of 0.04 over 20 outstanding agreements suggesting investors are buying way more calls than puts on contracts expiring on March 20th 2026. The total put volume is at 30.0, with calls trading at the volume of 9.0. This yields a 3.33 put-to-call volume ratio.
Open Interest Against March 20th 2026 Option Contracts
2026-03-20
The chart above shows Humacyte's distribution of open interest by maturity on contracts that have not yet been settled. The area between the two highest points is the projection of the price at expiration. Humacyte's open interest chart also provides vital information regarding the liquidity of an option. If there is no open interest for Humacyte's option, there is no secondary market available for investors to trade.
Humacyte Maximum Pain Price Across 2026-03-20 Option Contracts
Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of particular securities such as Humacyte close to expiration to expire worthless. So, Max pain occurs when market makers reach a net positive position across all options at a strike price where option holders stand to lose the most money. By contrast, Humacyte's option sellers may reap the most after selling more options than buying, causing them to expire worthless.
In The Money vs. Out of Money Option Contracts on Humacyte
Analyzing Humacyte's in-the-money options over time can help investors to take a profitable long position in Humacyte regardless of its overall volatility. This is especially true when Humacyte's options are deep in the money. These options can be identified using deltas that are over 0.75. Deep in-the-money Humacyte's options could be used as guardians of the underlying stock as they move almost dollar for dollar with Humacyte's stock while costing only a fraction of its price.
Humacyte's stock options are financial instruments that give investors the right to buy or sell shares of Humacyte common stock at a specified price for a given time period. Generally speaking, an option to purchase or sell Humacyte stock makes it part of the underlying stock when the option's price is tied to the movement of the underlying stock. If Humacyte's stock price goes up or down, the stock options follow.
The current year's Stock Based Compensation is expected to grow to about 7 M, whereas Total Stockholder Equity is projected to grow to (50 M). Humacyte In The Money Call Balance
When Humacyte's strike price is surpassing the current stock price, the option contract against Humacyte stock is said to be in the money. When it comes to buying Humacyte's options that are 'In the Money' or 'Out of the Money', the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
While 'out-of-the-money' option contracts written on Humacyte are typically viewed as the more aggressive, there are potential upsides to purchasing these types of options contracts. For one, the cost to buy an 'Out of the Money' option is lower than the cost to buy an 'In the Money' option. This cost-benefit is due to the fact that at the time of the purchase, 'Out of the Money' contracts have no intrinsic value. So, while the potential for a 100% loss is more significant, the cost and risk to enter the trade are lower.
Humacyte Current Options Market Mood
Humacyte's open interest and total value indicators provide investors with the necessary information to digest the overall options buildup for its expiring contracts. In addition, it helps Humacyte Stock's traders understand whether a recent fall or rise in the market is unreasonable and if the time has come to take contrarian positions. These ratios are calculated based on options trading volumes and current open interest.
Put-to-Call Open Interest
Put-to-Call Volume
Unfortunately, most Humacyte's options investors are not very successful. Humacyte's option open interest and volume spread between outstanding puts and calls are regarded by many investors as reliable indicators of the overall future market direction.
Rule 16 of the current Humacyte contract
Base on the Rule 16, the options market is currently suggesting that Humacyte will have an average daily up or down price movement of about 0.11% per day over the life of the 2026-03-20 option contract. With Humacyte trading at USD 1.27, that is roughly USD 0.001341. If you think that the market is fully incorporating Humacyte's daily price movement you should consider buying Humacyte options at the current volatility level of 1.69%. But if you have an opposite viewpoint you should avoid it and even consider selling them.
Purchasing Humacyte options can give investors a meaningful hedge against losses and, therefore, could be used conservatively to decrease the volatility of your portfolio. However, many options could also amount to little more than gambling, significantly enhancing your overall portfolio risk. One simple example of these aggressive strategies is the sale of "uncovered" Humacyte calls. Remember, the seller must deliver Humacyte stock to the call owner when a call is exercised.
Humacyte Option Chain
When Humacyte's strike price is surpassing the current stock price, the option contract against Humacyte stock is said to be in the money. When it comes to buying options that are ITM or OTM, the choice depends on your outlook for the underlying security, financial situation, and what you are trying to achieve.
Humacyte's option chain is a display of a range of information that helps investors for ways to trade options on Humacyte. In general, an option chain provides a helpful tool for investors to see all available option contracts, both puts, and calls, for Humacyte. It also shows strike prices and maturity days for a Humacyte against a given expiration period. The table below combines all the option information in the form of a chain but before you use it, remember that it entails significant risk and it is not for everyone. | Open Int | Strike Price | Current Spread | Last Price | |||
Call | HUMA260320C00005000 | 484 | 5.0 | 0.0 - 0.25 | 0.05 | Out |
Call | HUMA260320C00004500 | 7 | 4.5 | 0.0 - 0.45 | 0.09 | Out |
Call | HUMA260320C00004000 | 27 | 4.0 | 0.0 - 0.3 | 0.12 | Out |
Call | HUMA260320C00003500 | 318 | 3.5 | 0.0 - 0.5 | 0.18 | Out |
Call | HUMA260320C00003000 | 828 | 3.0 | 0.0 - 0.25 | 0.05 | Out |
Call | HUMA260320C00002500 | 595 | 2.5 | 0.0 - 0.25 | 0.09 | Out |
Call | HUMA260320C00002000 | 2914 | 2.0 | 0.1 - 0.25 | 0.14 | Out |
Call | HUMA260320C00001500 | 2580 | 1.5 | 0.15 - 0.35 | 0.22 | Out |
Call | HUMA260320C00001000 | 407 | 1.0 | 0.45 - 0.65 | 0.5 | In |
Call | HUMA260320C00000500 | 1 | 0.5 | 0.75 - 1.15 | 0.75 | In |
Put | HUMA260320P00000500 | 0 | 0.5 | 0.0 - 0.75 | 0.75 | |
Put | HUMA260320P00001000 | 2 | 1.0 | 0.0 - 0.75 | 0.2 | Out |
Put | HUMA260320P00001500 | 196 | 1.5 | 0.15 - 0.75 | 0.41 | In |
Put | HUMA260320P00002000 | 26 | 2.0 | 0.55 - 1.4 | 0.76 | In |
Put | HUMA260320P00002500 | 52 | 2.5 | 0.95 - 4.7 | 1.36 | In |
Put | HUMA260320P00003000 | 15 | 3.0 | 1.4 - 2.15 | 1.9 | In |
Put | HUMA260320P00003500 | 3 | 3.5 | 1.9 - 2.65 | 2.26 | In |
Put | HUMA260320P00004000 | 6 | 4.0 | 2.1 - 3.3 | 2.25 | In |
Put | HUMA260320P00004500 | 0 | 4.5 | 2.6 - 3.8 | 2.6 | In |
Put | HUMA260320P00005000 | 59 | 5.0 | 3.2 - 4.3 | 3.36 | In |
Humacyte Market Cap Over Time
Market Cap |
| Timeline |
Humacyte Total Stockholder Equity
Total Stockholder Equity |
|
Humacyte Corporate Management
| Harold Alterson | Senior Quality | Profile | |
| Sabrina Osborne | Executive People | Profile | |
| Dale Sander | Chief CFO | Profile | |
| Heather Connelly | Senior Quality | Profile | |
| William Scheessele | Chief Officer | Profile | |
| Yang MD | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Humacyte. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. For information on how to trade Humacyte Stock refer to our How to Trade Humacyte Stock guide.You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Humacyte. If investors know Humacyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Humacyte listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.27) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Humacyte is measured differently than its book value, which is the value of Humacyte that is recorded on the company's balance sheet. Investors also form their own opinion of Humacyte's value that differs from its market value or its book value, called intrinsic value, which is Humacyte's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Humacyte's market value can be influenced by many factors that don't directly affect Humacyte's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Humacyte's value and its price as these two are different measures arrived at by different means. Investors typically determine if Humacyte is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Humacyte's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.